Abstract
Nonhuman primates are useful for the study of age-associated changes in the brain and behavior in a model that is biologically proximal to humans. The Aβ and tau proteins, two key players in the pathogenesis of Alzheimers disease (AD), are highly homologous among primates. With age, all nonhuman primates analyzed to date develop senile (Aβ) plaques and cerebral β-amyloid angiopathy. In contrast, significant tauopathy is unusual in simians, and only humans manifest the profound tauopathy, neuronal degeneration and cogni-tive impairment that characterize Alzheimers disease. Primates thus are somewhat paradoxical models of AD-like pathology; on the one hand, they are excellent models of normal aging and naturally occurring Aβ lesions, and they can be useful for testing diagnostic and therapeutic agents targeting aggregated forms of Aβ. On the other hand, the resistance of monkeys and apes to tauopathy and AD-related neurodegeneration, in the presence of substantial cerebral Aβ ; deposition, suggests that a comparative analysis of human and nonhuman primates could yield informative clues to the uniquely human predisposition to Alzhei s disease.
Keywords: Aging, Alzheimer's disease, amyloid, cerebral amyloid angiopathy, monkeys, neurodegeneration, senile plaques, tauopathy, Nonhuman primates, Aβ lesions
Current Pharmaceutical Design
Title: Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy
Volume: 18 Issue: 8
Author(s): Eric Heuer, Rebecca F. Rosen, Amarallys Cintron and Lary C. Walker
Affiliation:
Keywords: Aging, Alzheimer's disease, amyloid, cerebral amyloid angiopathy, monkeys, neurodegeneration, senile plaques, tauopathy, Nonhuman primates, Aβ lesions
Abstract: Nonhuman primates are useful for the study of age-associated changes in the brain and behavior in a model that is biologically proximal to humans. The Aβ and tau proteins, two key players in the pathogenesis of Alzheimers disease (AD), are highly homologous among primates. With age, all nonhuman primates analyzed to date develop senile (Aβ) plaques and cerebral β-amyloid angiopathy. In contrast, significant tauopathy is unusual in simians, and only humans manifest the profound tauopathy, neuronal degeneration and cogni-tive impairment that characterize Alzheimers disease. Primates thus are somewhat paradoxical models of AD-like pathology; on the one hand, they are excellent models of normal aging and naturally occurring Aβ lesions, and they can be useful for testing diagnostic and therapeutic agents targeting aggregated forms of Aβ. On the other hand, the resistance of monkeys and apes to tauopathy and AD-related neurodegeneration, in the presence of substantial cerebral Aβ ; deposition, suggests that a comparative analysis of human and nonhuman primates could yield informative clues to the uniquely human predisposition to Alzhei s disease.
Export Options
About this article
Cite this article as:
Heuer Eric, F. Rosen Rebecca, Cintron Amarallys and C. Walker Lary, Nonhuman Primate Models of Alzheimer-Like Cerebral Proteopathy, Current Pharmaceutical Design 2012; 18 (8) . https://dx.doi.org/10.2174/138161212799315885
DOI https://dx.doi.org/10.2174/138161212799315885 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
A Summary of Electrospun Nanofibers as Drug Delivery System: Drugs Loaded and Biopolymers Used as Matrices
Current Drug Delivery Neuroprotective Appraisal of Methanolic Extract of Flowers of Nerium oleander in a Non Classical Rat Model of Alzheimer Disease
The Natural Products Journal Alzheimer: A Decade of Drug Design. Why Molecular Topology can be an Extra Edge?
Current Neuropharmacology Clearance of Genetic Variants of Amyloid β Peptide by Neuronal and Non-neuronal Cells
Protein & Peptide Letters Synthesis and Biological Evaluation of Berberine Derivatives as IBS Modulator
Letters in Drug Design & Discovery Pretreatment with Memantine Prevents Alzheimer-Like Alterations Induced by Intrahippocampal Okadaic Acid Administration in Rats
Current Alzheimer Research Adipose Tissue: The Link Between Obesity and Cardiovascular Disease
Cardiovascular & Hematological Disorders-Drug Targets Neuroinflammation: Microglial Activation During Sepsis
Current Neurovascular Research P2Y Receptors in the Mammalian Nervous System: Pharmacology, Ligands and Therapeutic Potential
CNS & Neurological Disorders - Drug Targets Vaccination to Alzheimer Disease. Is it a Promising Tool or a Blind Way?
Current Medicinal Chemistry Magnesium Lithospermate B Extracted from Salvia Miltiorrhiza, A Potential Substitute for Cardiac Glycosides
Mini-Reviews in Organic Chemistry Telomere/Telomerase System: A New Target of Statins Pleiotropic Effect?
Current Vascular Pharmacology Optimal Treatment of Severe Community-Acquired Pneumonia
Current Respiratory Medicine Reviews Subject Index To Volume 4
Current HIV Research Longitudinal Association between White Matter Hyperintensities and White Matter Beta-Amyloid Deposition in Cognitively Unimpaired Elderly
Current Alzheimer Research Lobar Atrophy in Frontotemporal Dementia: Diagnostic and Prognostic Implications
Current Alzheimer Research Pleiotropic Effects of Statins in Atherosclerotic Disease: Focus on the Antioxidant Activity of Atorvastatin
Current Topics in Medicinal Chemistry Structure-Activity Relationships of Flavonoids
Current Organic Chemistry Three Decades of P-gp Inhibitors: Skimming Through Several Generations and Scaffolds
Current Medicinal Chemistry Role of Monocarboxylate Transporters in Drug Delivery to the Brain
Current Pharmaceutical Design